SCA
NRXP icon

Sassicaia Capital Advisers’s NRX Pharmaceuticals NRXP Stock Holding History

Sassicaia Capital Advisers’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$33K – 31
2024
Q4 		$33K Buy
+15,000
New +$20.2K 0.8% 5

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Sassicaia Capital Advisers's NRXP Position: Q1 2025 in Review

Sassicaia Capital Advisers sold out of NRX Pharmaceuticals (NRXP) in Q1 2025, closing a stake of 15,000 shares — an estimated $33K sold.

Sassicaia Capital Advisers first reported a position in NRXP in Q4 2024 and held it in 1 quarter. The position peaked at $33K in Q4 2024. 22 funds tracked by Wall St. Rank hold NRXP as of Q1 2025.

  • Sassicaia Capital Advisers reported no remaining NRX Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 15,000 NRX Pharmaceuticals shares in Q1 2025, an estimated $33K.
  • Sassicaia Capital Advisers first reported a position in NRX Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Sassicaia Capital Advisers's NRX Pharmaceuticals position peaked at $33K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2025, filed 15 May 2025.